Medical corruption is shocking.
2065438+On April 22nd, 2005, Chen Mou, former director of the Staff Hospital of Hangzhou Iron and Steel Group Company, was sentenced to 8 years' imprisonment and confiscated 80,000 yuan of property. Salesmen of well-known pharmaceutical companies such as jiangsu hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as "Hengrui Pharma") paid bribes.
The reporter of "China Business News" noticed that the salesman of Hengrui Pharma had been involved in bribery cases of hospital-related personnel for many times. However, after each incident broke out, it seems that the enterprises involved can "get away with it", which does not prevent them from continuing to triumph in the market.
Participated in many cases
Hengrui Pharma is the largest R&D and production base of anti-tumor drugs and surgical drugs in China, and one of the most innovative large-scale pharmaceutical enterprises in China. It has always been an image of focusing on innovation in the industry.
The financial report shows that in 20 14, the company's main income was 7.452 billion yuan, up 20.14% year-on-year; Net profit151600 million yuan, up 22.4438+0% year-on-year. Accordingly, the market expenses in 20 14 years reached 2.58 billion yuan, accounting for 34.6% of the operating income of that year.
The high market cost may provide a convenient door for salespeople to pay bribes.
According to criminal judgment of Gongshu District People's Court in Hangzhou, Zhejiang Province, Song, a salesman in Hangzhou, Hengrui Pharma, gave the defendant RMB 20,000 in various names in order to have a good relationship with the former director of the staff hospital of Hangzhou Iron and Steel Group Company and thank him for his help in selling clarithromycin and other drugs in Hangzhou Iron and Steel Hospital.
Song's testimony proves that his hospitals in Hengrui Pharma and Hanggang have pharmaceutical businesses such as Nobon (clarithromycin), Beilai (ambroxol oral liquid), (sodium, potassium, magnesium and calcium injection), Weiertai (dirazole) and Ruifei. At the end of 2009, Song took over the business of Hangzhou Steel Hospital. Le Jia and violette entered Hanggang Hospital through their intermediary, and Chen Mou helped them. On holidays, Song gave Hangzhou Steel Hospital 20,000 yuan in cash. 20 10 or 20 1 1, Chen Mou said that he would go to Hainan or Xiamen University to share part of it. Song remembers that he seems to have taken a travel invoice for Song to reimburse. Song gave cash 1 10,000 yuan at the gate of the community or Hangzhou No.2 Middle School.
In fact, this is not the first time that a salesman in Hengrui Pharma has been involved in a medical corruption case in recent years.
20/kloc-in June, 2004, criminal judgment, the Intermediate People's Court of Suzhou City, Jiangsu Province, showed that the defendant took advantage of his position as the president and vice president of the First People's Hospital of Wujiang City, accepted the entrustment of Zhang, the director of the Suzhou office of Hengrui Pharmaceutical Group Co., Ltd., to seek benefits for him in medical procurement, and for the above reasons, he illegally accepted RMB 6,543,806 yuan from Zhang in his office of the First People's Hospital of Wujiang City twice.
In April of 20 14, criminal judgment, the people's court of Fugu County, Shaanxi Province, showed that from 2008 to 20 13, Wang, a salesman of jiangsu hengrui Pharmaceutical Co., Ltd., paid a bribe of 63,500 yuan to Liu, the director of the pharmacy department of Yulin Second Hospital, in order to let his drugs enter the second hospital for sale smoothly and keep the drugs he had sold from being eliminated.
According to Wang's testimony, he began to work as a sales clerk in jiangsu hengrui Pharmaceutical Co., Ltd. in 2005, and began to mainly do drug sales business in Yulin Second Hospital in 2006. Because the drugs selected by Yulin Second Hospital must be approved by Liu Weibin before they can enter the drug list, they were given to Liu Weibin 1 10,000 yuan in June 2008, Liu Weibin 1 10,000 yuan in June 2009 and Liu Weibin 1 10,000 yuan in September 22, 2009. In addition, in February, 2065438+2002, Liu Weibin was paid travel expenses 18500 yuan, and was given RMB 5000 yuan to thank him for his care in promoting drugs.
What's Hengrui Pharma's explanation for the salesman's involvement in the above case? Have relevant rectification measures been taken? Hengrui Pharma replied to this newspaper that the company was unaware of the above contents and was making further understanding and verification of the relevant situation.
It is worth noting that these salesmen involved in the case all appeared in the judgment as witnesses, but they were not marked for further treatment.
In fact, as early as June 30th, 2008, the Health Department of Henan Province named 36 pharmaceutical companies that paid bribes to hospitals and doctors in Henan Province, among which Hengrui Pharma was impressively listed. The variety involved at that time was oxaliplatin.
20 12 On August 22nd, a post signed "Hengrui Pharma's former medical representative" suddenly appeared on the Internet. The article titled "Exposing Hengrui Pharma's Illegal Acts" mainly exposes that Hengrui Pharma was suspected of paying high medical kickbacks to doctors during his business in the First Affiliated Hospital of Guangxi Medical University, Guangxi Cancer Hospital and other hospitals.
According to the documents disclosed on this website, more than 20 products such as paclitaxel, oxaliplatin, calcium folinate and cis-atracurium are all suspected of bribery. Many doctors from radiotherapy, chemotherapy, gynecology, cardiothoracic surgery, gastrointestinal gland surgery and other departments in the First Affiliated Hospital of Guangxi Medical University were born on the "bribery" list.
When interviewed by media reporters, Xu Guowen, then the representative of the company's securities affairs, firmly denied that Hengrui Pharma was suspected of bribery, which was completely false, and said that the libel incident had been resolved through judicial channels, but the matter was finally dropped.
All this has not stopped Hengrui Pharma from making great strides in the market.
The financial report shows that in the first quarter of 20 15, the company's operating income was 2.204 billion yuan, up 28.03% year-on-year, and its net profit was 547 million yuan, up 40.2% year-on-year. On May 27th, Hengrui Pharma's share price rose by 5. 19%, and its total market value reached101200 million yuan, making it the first pharmaceutical listed company to enter the club with a market value of 100 billion yuan.
Hidden rules are hard to break.
It has become a "hidden rule" for pharmaceutical companies to pay bribes to hospital-related personnel, and many pharmaceutical companies' business personnel have also played a disgraceful role in the Hangzhou Steel case.
The judgment of Gongshu District Court in Hangzhou also shows that from 2005 to 20 14, Jin Wei, deputy general manager of Zhejiang Pharmaceutical Co., Ltd., thanked the defendant for his help in the introduction of new drugs, the reuse of drugs, the dosage of drugs, etc., and repeatedly gave the defendant property worth RMB86,000. In the second half of 20 12, Huang Wei, manager of Zhejiang kangenbei pharmaceutical sales co., ltd., got a good relationship with the defendant and was taken care of in drug sales, and gave the defendant 3000 yuan in cash in his office.
The briber is jailed, and the briber may not be investigated for criminal responsibility because of the minor circumstances. Then, can pharmaceutical companies that benefit from it also "get away with it"?
In fact, the relevant state departments have long established a "blacklist" system for commercial bribery in the field of pharmaceutical purchase and sale. Once a pharmaceutical company commits commercial bribery, it will be listed in a bad record, which will affect its product bidding and purchasing.
According to the Provisions of the National Health Planning Commission on Establishing Bad Records of Commercial Bribery in the Field of Medicine Purchase and Sale, if an enterprise producing and selling drugs, medical devices and medical consumables or its agents or individuals give money or other benefits to the staff of medical and health institutions who purchase or use their drugs, medical devices and medical consumables, it will be included in the bad records of commercial bribery: if it is found by the people's court that it constitutes a crime of bribery, or if the crime is minor, it does not need to be punished, it will be exempted from criminal punishment according to the provisions of the Criminal Law. If the circumstances of accepting bribes are minor, the people's procuratorate decides not to prosecute.